Comparing iBio (IBIO) and The Competition

iBio (NASDAQ:IBIO) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare iBio to similar businesses based on the strength of its analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk and Volatility

iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, iBio’s competitors have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for iBio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1	0	4	2	3.00
iBio Competitors	9782	15046	45274	1571	2.54

iBio presently has a consensus price target of $6.00, suggesting a potential upside of 650.09%. As a group, “Biotechnology” companies have a potential upside of 99.61%. Given iBio’s stronger consensus rating and higher possible upside, equities analysts clearly believe iBio is more favorable than its competitors.

Institutional and Insider Ownership

7.9% of iBio shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 1.5% of iBio shares are held by company insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares iBio and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
iBio	$100,000.00	-$33.04 million	-2.35
iBio Competitors	$732.46 million	$13.53 million	-10.01

iBio’s competitors have higher revenue and earnings than iBio. iBio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares iBio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
iBio Competitors	-9,054.47%	-198.89%	-30.64%

About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.